MARKET

ENDP

ENDP

Endo Intl
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.63
-0.26
-4.41%
After Hours: 5.63 0 0.00% 17:20 04/20 EDT
OPEN
5.72
PREV CLOSE
5.89
HIGH
5.80
LOW
5.57
VOLUME
3.90M
TURNOVER
--
52 WEEK HIGH
10.89
52 WEEK LOW
2.710
MARKET CAP
1.30B
P/E (TTM)
11.23
1D
5D
1M
3M
1Y
5Y
Polyps Market 2021 Top manufacturers Records are Millennium Surgical,Black Smith Surgical,B. Braun , Share & Trends Analysis 2025
Apr 20, 2021 (The Expresswire) -- “ Polyps Market “ Size, Status and Market Insights 2021, ,Polyps Market By Type (Benign Polyp,Pre-Malignant Polyp,,), By...
The Express Wire · 19h ago
Cancer Pain Management Solutions Industry Size,Share,Growth Factors 2021 | Top Leading Countries, Companies, Consumption, Drivers, Trends, Forces Analysis, Revenue, Challenges and Global Forecast 2026
Apr 20, 2021 (The Expresswire) -- Global Cancer Pain Management Solutions Market Research Report has In-Depth Collective analysis of different factors that...
The Express Wire · 19h ago
Opioids Agonist Drugs Market Analysis & Trends 2021-2028: High Growth in Emerging Economies and Expansion of the Automotive & Transportation Industry By Ameco Research
pune, India, Tue, 20 Apr 2021 01:02:55 / Comserve Inc. / -- The global Opioids Agonist Drugs market is segmented by company, region (country), by Type, and...
Comserve · 20h ago
Lignocaine Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2021-2028 By Ameco Research
pune, India, Mon, 19 Apr 2021 23:02:28 / Comserve Inc. / -- The global Lignocaine market size is projected to reach US$ 213 million by 2027, from US$ 194.8...
Comserve · 22h ago
Opioids Agonist Drugs Market 2021 : Worldwide Market Size with Top Countries Data, Segmentation Analysis, Value Chain and Key Trends by 2025
Apr 19, 2021 (The Expresswire) -- According to 360 Research Reports, the “Opioids Agonist Drugs Market" 2021 by Types (Codeine, Fentanyl, Meperidine,...
The Express Wire · 22h ago
UPDATE 4-J&J, other drugmakers go to trial in California in $50 bln case over 'deadly legacy' of opioids
reuters.com · 1d ago
DJ Drugmakers Accused of Causing Opioid Addiction in Trial
Dow Jones · 1d ago
Benign Prostatic Hyperplasia (BPH) Medication Market: By Company Analysis, SWOT, Market Strategy and Global Forecast 2021-2027
Apr 19, 2021 (Market Stats News via COMTEX) -- The latest report as Benign Prostatic Hyperplasia (BPH) Medication Market acknowledges Size, Application...
Market Stats News · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ENDP. Analyze the recent business situations of Endo Intl through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ENDP stock price target is 7.70 with a high estimate of 12.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 300
Institutional Holdings: 202.75M
% Owned: 87.96%
Shares Outstanding: 230.50M
TypeInstitutionsShares
Increased
55
21.46M
New
32
1.46M
Decreased
64
14.24M
Sold Out
24
2.87M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.59%
Pharmaceuticals & Medical Research
+0.33%
Key Executives
Chairman/Director
Paul Campanelli
President/Chief Executive Officer/Director
Blaise Coleman
Chief Operating Officer/Executive Vice President
Terrance Coughlin
Executive Vice President
Patrick Barry
Executive Vice President
Domenico Ciarico
Executive Vice President
Domenic Ciarico
Executive Vice President
Rahul Garella
Executive Vice President
Matthew Maletta
Senior Vice President/Chief Accounting Officer/Controller
Jack Boyle
Independent Director
Mark Barberio
Independent Director
Jennifer Chao
Independent Director
Shane Cooke
Independent Director
Nancy Hutson
Independent Director
Michael Hyatt
Independent Director
Roger Kimmel
Independent Director
William Montague
Independent Director
M. Christine Smith
No Data
  • All
  • Financials
  • Insiders
More
About ENDP
Endo International plc is a generics and specialty branded pharmaceutical company. The Company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals and International Pharmaceuticals. It has a portfolio of branded pharmaceuticals offered by its U.S. Branded Pharmaceuticals segment that includes brand names, such as Lidoderm, OPANA ER, Voltaren Gel, Percocet, Fortesta Gel, Testim, TESTOPEL, Aveed, Supprelin LA and XIAFLEX. Its non-branded U.S. Generic Pharmaceuticals portfolio consists of products, such as tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics and patches. The Company's generics portfolio has a range of dosage forms and delivery systems. The International Pharmaceuticals segment includes various specialty pharmaceutical products for the Canadian, Latin American and world markets.

Webull offers kinds of Endo International PLC stock information, including NASDAQ:ENDP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENDP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ENDP stock methods without spending real money on the virtual paper trading platform.